High vitreous TNF-Alpha and vascular endothelial growth factor levels as a risk factor for proliferative diabetic retinopathy in type 2 diabetes mellitus patients

被引:0
作者
Suryathi, Ni Made Ari [1 ]
Suastika, Ketut [2 ]
Andayani, Ari [1 ]
Pantjawati, Ni Luh Diah [1 ]
Surasmiati, Ni Made Ayu [1 ]
Manuaba, Ida Bagus Putra [3 ]
机构
[1] Univ Udayana, Ophthalmol Dept, Fac Med, Denpasar, Bali, Indonesia
[2] Univ Udayana, Fac Med, Internal Med Dept, Denpasar, Bali, Indonesia
[3] Univ Udayana, Fac Math & Sci, Chem Dept, Denpasar, Bali, Indonesia
关键词
TNF Alpha; Vascular Endothelial Growth Factor; Proliferative Diabetic Retinopathy; Vitreous; EXPRESSION PROFILES; BIOMARKERS; CYTOKINES;
D O I
10.15562/bmj.v13i3.5298
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Type-2 diabetes mellitus is a metabolic disease that can cause various complications. One of the complications of type 2 DM that can occur in the eyes is Proliferative Diabetic Retinopathy (PDR). PDR can cause a sharp decrease in vision and even blindness. The global prevalence of DM is 8.3%, and the prevalence of DM in Bali is 5.9%. PDR complications occurred in 26.3% of type 2 DM patients. Therefore, this study aims to prove the role of TNF-alpha in the inflammatory pathway and the role of VEGF in the angiogenesis pathway as risk factors for PDR in type 2 DM. Methods: This study is a case-control study, and matching is carried out for age and gender. A total of 38 subjects were enrolled in this study, where the case group was type 2 DM patients with PDR who underwent vitrectomy, and the controls were patients without type 2 DM who underwent vitrectomy according to medical indications. The levels of TNF-alpha and VEGF in the vitreous were measured using the Enzyme-Linked Immunosorbent Assay (ELISA) technique. Result: TNF-alpha and VEGF's cut-off points are 15.795 pg/ml and 22.980 pg/ml. OR of TNF-alpha was 5.13; 95% CI: 2.88-6.95; p= 0.001 (<0.05). OR of VEGF was 3.86; 95% CI: 1.83-3.79; p=0.017 (<0.05). The multinominal logistic regression analysis test showed that OR TNF-alpha was dominant as a risk factor for PDR, followed by VEGF. OR TNF-alpha=5.88; 95% CI: 2.36-6.79; p=0.008 (<0.05). OR VEGF= 3.1; 95% CI: 1.02-3.37; p=0.015 (<0.05). Conclusion: This study proves that high vitreous levels of TNF-alpha and VEGF are risk factors for PDR in type 2 DM. These findings strengthen the theory of PDR pathogenesis through the inflammatory pathway (TNF-alpha) and the angiogenesis pathway (VEGF) in type 2 DM.
引用
收藏
页码:1307 / 1311
页数:5
相关论文
共 34 条
  • [21] Toll like receptor signaling in "inflammaging": microRNA as new players
    Olivieri, Fabiola
    Rippo, Maria Rita
    Prattichizzo, Francesco
    Babini, Lucia
    Graciotti, Laura
    Recchioni, Rina
    Procopio, Antonio Domenico
    [J]. IMMUNITY & AGEING, 2013, 10
  • [22] DOK3 Negatively Regulates LPS Responses and Endotoxin Tolerance
    Peng, Qisheng
    O'Loughlin, Jason L.
    Humphrey, Mary Beth
    [J]. PLOS ONE, 2012, 7 (06):
  • [23] Vitreous and Serum Levels of Platelet-Derived Growth Factor and Their Correlation in Patients with Proliferative Diabetic Retinopathy
    Praidou, Anna
    Klangas, Ioannis
    Papakonstantinou, Eleni
    Androudi, Sofia
    Georgiadis, Nikolaos
    Karakiulakis, George
    Dimitrakos, Stavros
    [J]. CURRENT EYE RESEARCH, 2009, 34 (02) : 152 - 161
  • [24] Serum MiRNA Biomarkers serve as a Fingerprint for Proliferative Diabetic Retinopathy
    Qing, Shao
    Yuan, Songtao
    Yun, Chen
    Hui, Hang
    Mao, Pingan
    Wen, Fan
    Ding, Yuzhi
    Liu, Qinghuai
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2014, 34 (05) : 1733 - 1740
  • [25] Rasier R, 2013, Guoji Yanke Zazhi (Int Eye Sci), V13, P2365
  • [26] Sadda S R., 2022, Ryans Retina
  • [27] The estimated healthcare cost of diabetic retinopathy in Indonesia and its projection for 2025
    Sasongko, Muhammad Bayu
    Wardhana, Firman Setya
    Febryanto, Gandhi Anandika
    Agni, Angela Nurini
    Supanji, Supanji
    Indrayanti, Sarah Rizqia
    Widayanti, Tri Wahyu
    Widyaputri, Felicia
    Widhasari, Idhayu Anggit
    Lestari, Yeni Dwi
    Adriono, Gitalisa Andayani
    Sovani, Iwan
    Kartasasmita, Arief Sjamsulaksan
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2020, 104 (04) : 487 - 492
  • [28] Prevalence of Diabetic Retinopathy and Blindness in Indonesian Adults With Type 2 Diabetes
    Sasongko, Muhammad Bayu
    Widyaputri, Felicia
    Agni, Angela Nurini
    Wardhana, Firman Setya
    Kotha, Satyaprabha
    Gupta, Prateek
    Widayanti, Tri Wahyu
    Haryanto, Supanji
    Widyaningrum, Rifa
    Wong, Tien Yin
    Kawasaki, Ryo
    Wang, Jie Jin
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2017, 181 : 79 - 87
  • [29] Diabetic Retinopathy: Vascular and Inflammatory Disease
    Semeraro, F.
    Cancarini, A.
    dell'Omo, R.
    Rezzola, S.
    Romano, M. R.
    Costagliola, C.
    [J]. JOURNAL OF DIABETES RESEARCH, 2015, 2015
  • [30] Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects
    Stewart, Michael W.
    Flynn, Harry W., Jr.
    Schwartz, Stephen G.
    Scott, Ingrid U.
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (09) : 1277 - 1287